MIRCERA.com

The efficacy and safety of MIRCERA has been evaluated in four phase II and six phase III correction and maintenance studies. More than 2,700 patients participated in the largest phase II–III registration programme ever conducted for a drug treating renal anaemia.¹

 

This section aims to give you an overview of the correction and maintenance studies in patients with CKD-associated anaemia.

 

Information on clinical trials sponsored by F. Hoffmann-La Roche can be found on the Clinical Trial Protocol Registry and Results Database

 

References:

 

1. MIRCERA^® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.